Data Access Governance by Shabani, Mahsa et al.
19
Data Access Governance
Mahsa Shabani, Adrian Thorogood and Madeleine Murtagh
19.1 introduction
Enabling researchers’ access to large volumes of health data collected in both research and
healthcare settings can accelerate improvements in clinical practice and public health. Because
the source and subject of those data are people, data access governance has been of concern to
scientists, ethics and regulatory scholars, policymakers and citizens worldwide. While research-
ers have long provided colleagues access to data in an ad hoc fashion, many research funders –
e.g. US National Institutes of Health, Wellcome, Bill and Melinda Gates Foundation, United
Kingdom Research and Innovation, European Research Council – journals,1 professional
societies and associations,2 and regulators now systematically promote the deposit of research
data in repositories that aim to provide responsible and timely access to data. Data sharing aims
to enable meta-analyses and creative (re)uses, reduce duplicative effort in data generation, and
improve reproducibility through validation studies, so as to support data-intensive research and
thereby improve human health. In many countries, routinely collected healthcare data is also
increasingly being made available to researchers. In both research and healthcare contexts,
technical and governance strategies for promoting responsible data sharing and access continue
to evolve.
The broad sharing of health research data promises many benefits, but it can also involve risks.
Health research data can reveal sensitive information about individuals (in legal terms, data
subjects) and their relatives, posing risks to privacy and of discrimination and stigmatisation.
Broad sharing of health research data can also raise professional concerns for the researchers or
organisations who produce data in terms of receiving adequate credit and recognition for their
efforts in collecting, curating and analysing data.3 Likewise, commercial research companies
may be concerned their data will be appropriated or misused by competitors. Data access
governance aims to promote organisational, scientific and societal interests in data re-use, while
protecting the rights and interests of the range of stakeholders with an interest in data. Data
access governance manages who has access to data, for what purposes, and under what
1 D. Taichman et al., ‘Sharing Clinical Trial Data: A Proposal from the International Committee of Medical Journal
Editors’, (2016) Annals of Internal Medicine, 164(7), 505–506.
2 ACMG Board of Directors, ‘Laboratory and Clinical Genomic Data Sharing Is Crucial to Improving Genetic Health
Care: A Position Statement of the American College of Medical Genetics and Genomics’, (2017)Genetics in Medicine,
19(7), 721– 722.
3 M. Murtagh et al., ‘International Data Sharing in Practice: New Technologies Meet Old Governance’, (2016)
Biopreservation and Biobanking, 14(3), 231–240.
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conditions. Governance mechanisms include policies, due diligence processes, data access
agreements and monitoring. Data access governance is closely linked to the concept of data
stewardship, where organisations aim to ensure data are shared widely in the interest of science
and society, while also mitigating associated ethical, societal and privacy risks.4
In contemporary data-driven science, data access governance often involves Data Access
Committees (DACs) as the key institutional setting in which access decisions are made.
DACs are diverse and may be composed of individuals with a range of relevant expertise,
including familiarity with the scientific area, privacy and security, and research ethics.5 As
Lowrance notes, ‘. . .[s]ome DACs are formally constituted and appointed, while some are more
casual. Some publish their criteria, decisions and decision rationales, but most don’t. Some
directly advise the data custodians, who then make the yes/no (or revise-and-reapply) access
decisions. But many DACs make binding decisions’.6
Against this backdrop, this chapter examines the topic of data access governance. We discuss
the underlying values and goals of data access governance, focusing in particular on the
scientific and social implications for open access and data sharing, on the rights and interests
of data subjects as well as those of data producers, and on the ethical conduct of data sharing.
We contrast the general structural and normative components of open and controlled data
access. We then present existing data access arrangements of organisations and repositories that
exemplify varying modes of good practice. We argue these models exemplify the tension
between promoting open access to databases on the one hand, and, on the other, protecting
the rights and interests of the parties involved, including data subjects, researchers, funding
organizations and commercial entities. We suggest that principles of transparency, fairness and
proportionality in consideration of all stakeholders’ interests and values is key to achieving this
balance. We conclude by discussing existing challenges in data access governance, including
potential conflicts between various stakeholders’ views and interests, resource issues, (mis)
coordination between oversight bodies, and the need for better harmonisation of access policies
and procedures.
19.2 goals of data access governance
Key goals of data access governance aim to strike a balance between protecting data subjects and
data producers’ rights and interests, while also promoting broad access to data to advance
scientific research in the public interest.
19.2.1 Protecting Data Subject Rights and Interests and
Promoting Research Integrity and Ethics
Data access governance supports research ethics principles for research involving human
subjects. Minimising privacy risks to participants, respecting participant autonomy, and
holding researchers accountable for the scientific validity and ethical conduct of research
through research ethics committee (REC) approval and oversight, are key goals of governance
4 The Expert Panel on Timely Access to Health and Social Data for Health Research and Health System Innovation,
‘Accessing Health and Health-Related Data in Canada’, (Council of Canadian Academies, 2015).
5 Murtagh et al., ‘Better Governance, Better Access: Practising Responsible Data Sharing in the METADAC
Governance Infrastructure’, (2018) Human Genomics, 12(1), 24.
6 W. W. Lowrance, Privacy, Confidentiality, and Health Research (Cambridge University Press, 2012).
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of data access.7 These goals are increasingly furthered by engaging communities in the design
of governance.
Privacy and security: Data access governance can protect participant privacy in several ways.
Data access agreements, which are signed by data custodians and data users, typically include
requirements regarding protecting privacy and security. Privacy safeguards include restrictions
on unauthorised individual-level linkage of datasets, which may increase the re-identifiability of
data, or prohibitions on attempting to re-identify participants. The greater the combinations of
individual-level data for any given individual, the more likely re-identification becomes. Privacy
rules in access processes are therefore often designed to control the level of individual-level data
linkage. Security safeguards may include general or specific requirements to adopt physical,
organisational, and technical protections, as well as data breach reporting obligations.
Respect for the provisions of ethical approvals: Data access governance models often aim to
ensure users respect high standards of scientific integrity, and meet the ethical requirements
related to compatibility of downstream use of data with the original consent obtained from the
participants at the time of enrolment to a study and data collection. Where researchers have
stated that data will only be used for certain kinds of research – e.g. disease-specific – this
condition will inform the review of an access proposal by the relevant oversight bodies, notably
DACs. Data access review may be informed by the following questions:8 Does the application
violate – or potentially violate – any of the ethical permissions granted to the study or any of the
consent forms signed by the study participants or their guardians? Does the application run a
significant risk of upsetting or alienating study participants or thereby reducing their willingness
to remain as active participants in the research? Does the application run a significant risk of
bringing disrepute to study, repository or steward and thereby reducing participant trust and
willingness to remain as active participants in the research?
Respect for communities and relevant stakeholders: Responding to relevant stakeholders
including communities’ concerns and seeking to strike a balance between the views of different
groups is fundamental to respecting these communities. This may mean championing the rights
of less powerful groups and taking steps to seek out their views and actively responding to those
views. In the context of data access, stakeholders include study participants and communities
who provide the data, study managers and the researchers who develop the data and related
resources, researchers who wish to access those data, the funders who support the studies which
produce the data and the public who are the ultimate funders as well as beneficiaries of research.
Each of these groups has a legitimate and vested interest in the responsible and respectful uses of
data and provide a unique perspective on how such governance can be achieved. For example,
study participants and community representatives sitting on oversight committees such as DACs
can provide a unique insight into what other study participants may view as acceptable uses
of data.
19.2.2 Data Producer Rights and Interests
One goal of access controls is to protect the rights and interests of the researchers or institutions
generating data. Academically, researchers compete for high-impact publications and, in turn,
for academic positions and promotions. Commercially, researchers and research institutions
7 M.Aitken et al., ‘Consensus Statement on Public Involvement and Engagement with Data-Intensive Health Research,’
(2019) International Journal of Population Data Science, 4(1).
8 Murtagh et al., ‘METADAC Governance Infrastructure’, 24.
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may compete to develop commercial applications from research findings. These considerations
are often addressed through publication and commercialisation clauses in data access
agreements.
Data access governance may include publication policies that seek to ensure that data
producers are appropriately recognised for their contribution to science. Given that publication
remains the major currency in academia, there may be a tendency for data producers to request
co-authorship as a condition of access. This is discouraged for reasons of scientific freedom and
accountability. Having independent DAC members adjudicating access is one remedy to the
potential conflicts of interest in such practices. A compromise position is sometimes used
whereby the data producer has a right to review manuscripts before publication, or to at least
to be informed in advance of forthcoming publications based on (re)analysis of shared datasets.
Commercialisation policies aim to ensure that the data producer benefits from, or at least does
not have its competitive position harmed by, downstream use of data.
Finally, responsible data access governance requires transparency, fairness and proportionality
towards participants and other stakeholders. Transparency can be improved by the publishing of
policies and procedures, as well as publication of approved data recipients and plain language
summaries or abstracts of approved uses. Moreover, ensuring timely and consistent access review
without imposing unnecessary constraints on data access are of salient importance with regard to
fairness. Where data governance seeks to achieve competing goals of openness and privacy
protection, as well as meeting social and participant expectations of data use, a proportionate
balance needs to be struck. Proportionality may call for different types of access controls to be
applied to different types of data. Increasingly, there is emphasis that the balance between public
benefit and individual risks be evidence-based.9
19.3 data access governance: policies, processes,
agreements and oversight
The values and goals of data access governance are operationalised through the policies and
practices of DACs and various models of data access.
19.3.1 Controlled Versus Open Access Data
The nature of data – and the associated ethical, policy and legal issues – largely determines the
access model, which can range from open to controlled to closed. Open access models generally
make data available to any user, anywhere, over the internet, without financial or technical
constraints. The Human Genome Project, for example, which sequenced the entire human
genome, shared the sequence data openly. Subsequent publicly-funded projects sequenced
more individuals and combined these data with richer social, demographic and clinical data,
prompting concerns about the privacy of data subjects. Controlled access models emerged to
ensure data could still be shared broadly with qualified and trusted researchers, while also
protecting the privacy of data subjects and sometimes also the interests of researchers producing
data. In controlled access, access is managed by a REC or increasingly by a specialised DAC,
9 M. Shabani et al., ‘Who Should Have Access to Genomic Data and How Should They Be Held Accountable?
Perspectives of Data Access Committee Members and Experts’, (2016) European Journal of Human Genetics, 24(12),
1671–1675; P. Burton et al., ‘Policies and Strategies to Facilitate Secondary Use of Research Data in the Health
Sciences’, (2017) International Journal of Epidemiology, 46(6), 1729–1733.
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which reviews requests for data access. In this regard, DACs often carry out a due diligence
review of access requests and may hold deliberations over the scientific, feasibility and ethical
aspects of the request. This is in line with the recommendations issued by the Organisation for
Economic Co-operation and Development’s (OECD) Council on Health Data Governance
that review and approval processes should involve an evidence-based assessment and adhere to
principles of transparency, objectivity and fairness. In addition, the OECD’s recommendations
underline the importance of independent multi-disciplinary review with an ultimate aim of risk
mitigation for individuals and society.10
19.3.2 Data Access Agreements
One component of both controlled and open access models is the data agreement (termed ‘data
transfer’, ‘data access’ or ‘data use’ agreement), which establishes the conditions governing the
accessing researcher’s use of the data. The terms of data access agreements typically address data
subject protections, including prohibition on unauthorised linkage of individual-level data and
attempts to re-identify participants, respect for consent-based use conditions and ensuring
appropriate security safeguards are in place. The terms may also include protections for the
rights and interests of the researchers producing data, such as publication embargoes to allow
data producers the first attempt at publication or intellectual property clauses governing owner-
ship of downstream commercialisation. Benefit-sharing clauses are important in countries with
emergent research infrastructures. Other clauses may serve multiple stakeholders, such as
obligations to only use data for specified purposes. Still other clauses may address the interests
of science and society, such as requirements for open access publication, or to share analysis
code or derived datasets. While data access agreements are legally binding if designed
properly, their practical enforceability, especially across borders, is largely untested and remains
a concern.11 Especially where terms are associated with open access data, they are typically
meant more as a means of communicating community norms to users.
19.3.3 Monitoring of Data Use
DACs may additionally develop tools and mechanisms to maintain ongoing oversight of
downstream data uses. For instance, data users may be required to provide periodic reports
regarding the projects in which data are being used. In addition, data users may be asked to
report to the DAC the publications resulting from the data use, or issues arising from special
conditions of access, e.g. risk management strategies for sensitive or potentially ‘sensational’
research, or return of incidental findings. Such oversight may enable the DACs to check
compliance of the data uses, but implementation requires infrastructure and human resources
that may be burdensome for DACs that do not have dedicated funding. There may also be
important burdens – e.g. reporting or transparency obligations – placed on data users that
discourage frivolous use. Research teams releasing data or DACs may have little ability to
monitor data users or to directly sanction them for misuse, except by withdrawing or refusing
access in the future. Some level of accountability is available via community reporting and
10 OECD, ‘Recommendations on Health Data Governance’, (OECD), www.oecd.org/els/health-systems/health-data-
governance.htm.
11 Burton et al., ‘Policies and Strategies for Secondary Data Use of Data’; Global Alliance for Genomics & Health,
‘GA4GH Accountability Policy 2016’, (Global Alliance for Genomics & Health, 2016).
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norms. Research institutions, funders, journals and databases themselves may have mechanisms
to hold researchers accountable for respecting their commitments.12
19.3.4 Maintaining Transparency
The constitution of DACs shape how policies and governance mechanisms are implemented
in practice. DACs are the site around which tensions between the competing interests of
stakeholders may play out and therefore, examining how they do or do not maintain
transparency allows scrutiny of those governance processes. DAC members may be part of
the scientific team that generated the data, though the independence of members is often
advocated in order to avoid conflicts of interest. Real or perceived conflicts of interest may
arise where the researcher who collected the data restricts access to potential competitors,
described as data ‘hugging’ or hoarding by those advocating data sharing.13 And yet, data
producers have important expertise: they know the affordances and limits of the data as well
as its provenance. In some DACs, this expertise is recognised by including members of the
study team in an advisory role.14 Furthermore, all stakeholders should have some representa-
tion in governance of data access including as decision-making members of DACs.
Stakeholder engagement may also comprise forms of transparency, for example through
publication of high-quality plain language summaries to communicate how study data are,
or will be, used.
19.4 best practice examples
Depending on the organisation or its specific needs, data access governance can emphasise
different governance-related values and goals.
19.4.1 Multi-study Access: European Genome-Phenome Archive (EGA)
An example of the local access management model is the collection of study DACs under the
framework of the EGA. EGA is a database of all types of ‘sequence and genotype experiments,
including case-control, population, and family studies, hosted at the European Bioinformatics
Institute’.15 According to the EGA website: ‘The EGA will serve as a permanent archive that will
archive several levels of data including the raw data (which could, for example, be re-analysed in
the future by other algorithms) as well as the genotype calls provided by the submitters.’16 Data
submitters via EGA maintain control over the downstream uses of datasets via DACs located in
the original study or consortium. An advantage of local data access review is that data generators
who are familiar with the dataset can stay involved in the process of review and inform the access
review procedure. The disadvantage of this model is that the access control is entirely left to the
local committees, making it hard if not impossible to track/audit whether all data access requests
are being handled in a timely manner.
12 Global Alliance for Genomics & Health, ‘GA4GH Accountability Policy 2016’.
13 Murtagh et al., ‘International Data Sharing’.
14 Murtagh et al., ‘METADAC Governance Infrastructure’.
15 European Genome-phenome Archive (EGA), ‘Introduction’, (EGA, 2019), www.ega-archive.org/about/introduction.
16 Ibid.
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19.4.2 Centralised Access: Database of Genotypes and Phenotypes (dbGaP)
In contrast, dbGaP exemplifies a centralised approach to managing data access requests. The
dbGaP is designed by the National Institutes of Health (NIH) to archive and distribute the
results of studies that have investigated the interaction of genotype and phenotype. Within this
database, sixteen DACs ‘review requests for consistency with any data use limitations and
approve, disapprove or return requests for revision’, except for large studies in which a local
DAC leads access review.17 The centralised access model seems advantageous for smaller
research groups who lack resources to establish their own data access review infrastructure.
However, the handling of data access requests centrally may lead to latency in data access, due to
complex administrative arrangements.
19.4.3 Tiered Access: International Cancer Genome Consortium/25K Initiative
The International Cancer Genome Consortium (now called the 25K Initiative) was a large-scale
genomics research initiative aiming to generate and share 25,000 whole genome sequences from
fifteen jurisdictions to better understand the genetic changes occurring in different forms of
cancer.18 The International Cancer Genome Consortium (ICGC) adopted a tiered access
approach, with open access for data unlikely to be linked to other data that could re-identify
individual participants, and controlled access for more sensitive data such as raw sequence and
genotype files – though the exact data types in these two categories evolved over time.19 These
more sensitive data can only be accessed through the Data Access Committee Office (DACO) to
protect the privacy and reasonable expectations of study participants, uphold scientific commu-
nity norms of attribution and publication priority, and ensure the impartiality of access decisions.
The DACO reviews the purpose and relevance of research proposals, and the trustworthiness of
applicants to protect participant privacy and data security. The ICGC adopted a plain language
access agreement restricting users from establishing parasitic intellectual property on primary
data or attempting to re-identify individual participants, with signatures from the principal
investigator and institutional signing official. Recognising that requirements for ethics review
vary from country to country, the DACO asks applicants to indicate if their study of ICGC data
requires local ethics approval.
19.4.4 Independent, Interdisciplinary Access Involving Stakeholder Participation in
Decisions: METADAC (Managing Ethical, Socio-Technical and Administrative
Issues in Data Access)20
METADAC provides data access governance for only the most sensitive data and data combin-
ations (as well as sample access). While separating access in this way produces a complex data
governance setting for researchers, the devolvement to different degrees of scrutiny for differently
risky data allows resources for human-mediated decision making, where this is necessary and
17 D. Paltoo et al., ‘Data Use Under the NIH GWAS Data Sharing Policy and Future Directions’, (2014) Nature
Genetics, 46(9), 934–938, 934.
18 International Cancer Genome Consortium, ‘About Us’, (International Cancer Genome Consortium, 2018), www.icgc
.org/about-us.
19 Y. Joly et al., ‘Data Sharing in the Post-Genomic World: The Experience of the International Cancer Genome
Consortium (ICGC) Data Access Compliance Office (DACO)’, (2012) PLoS Computational Biology, 8(7), e1002549.
20 Murtagh et al., ‘METADAC Governance Infrastructure’.
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allows administrative or algorithm-based decisions for low risk data types. The human-mediated
decisions made by METADAC include a proportionate review process for routine-but-sensitive
data access applications and full committee decision-making for the remaining sensitive data
access applications. The METADAC committee comprises a highly multidisciplinary commit-
tee, including study-facing members (currently drawn from the participants of longitudinal
studies not regulated by METADAC), with non-voting representation from the studies (includ-
ing their technical teams) and the funders of these studies. Data access under METADAC does
not require additional ethical approval as data sharing is based on tissue bank approval under the
Human Tissue Act 2004,21 study ethical approval and/or explicit participant consent to sharing.
METADAC’s key criteria for access follow precisely the questions outlined in ‘Respect for the
provisions of ethical agreements’ above. The METADAC committee does not review the
scientific merit of data access applications except in the case of finite resources (i.e. samples).
19.4.5 Data Producers’ Rights and Interests: ClinicalStudyDataRequest
ClinicalStudyDataRequest.com is a portal facilitating access to patient-level data from clinical
studies carried out by pharmaceutical companies and academic researchers.22 The portal
involves independent review of proposals as well as protections for participant privacy and
confidentiality. A major differentiator of this access model from the publicly funded genomic
research context is protection of commercial interests. For pharmaceutical company-sponsored
trials, the data sharing agreement requires users to keep all information provided confidential, in
part to protect commercially sensitive information.23 The user must also agree to give the
sponsor an exclusive licence to any new intellectual property generated from the study. The
agreement also requires users to publish or otherwise publicly disclose their results, which helps
to ensure research is pursued for verification rather than commercial purposes.
19.4.6 Transparency and Reflexive Governance: UK Biobank
(Ethics and Governance Framework)
In the late 2000s, in what would be an example of reflexive data access governance,24 the UK
Biobank revised its Ethics and Governance Framework (to address challenges that were current
at the time). More specifically, the UK Biobank had originally committed to destroy the data of
participants who chose to withdraw from the biobank. However, it soon realised that it could not
uphold this commitment due to technical issues.25 These issues included the establishment of
IT systems that made it impossible to destroy data completely in order ‘to protect the integrity
and security of those people who have taken part’.26 One year after identifying these issues, the
21 This Act applies to England, Northern Ireland and Wales. With the exception of section 45, which regulates DNA
analysis, the Act does not extend to Scotland.
22 ClinicalStudyDataRequest, ‘Home’, (ClinicalStudyDataRequest), www.clinicalstudydatarequest.com/Default.aspx.
23 ClinicalStudyDataRequest, ‘Data Sharing Agreement’, (ClinicalStudyDataRequest),
www.clinicalstudydatarequest.com/Help/Help-Data-Sharing-Agreement.aspx.
24 G. Laurie, ‘Reflexive Governance in Biobanking: On the Value of Policy Led Approaches and the Need to Recognise
the Limits of Law’, (2011) Human Genetics, 130(3), 347–356.
25 UK Biobank, ‘Revision of the UK Biobank Ethics and Governance Framework: ‘No Further Use’ Withdrawal
Option’, (UK Biobank, 2007), www.egcukbiobank.org.uk/sites/default/files/Right%20to%20withdraw%20from%20UK
%20Biobank.pdf.
26 UK Biobank, ‘“NO FURTHER USE” Withdrawal Option – UK Biobank’s Commitment to Your Wishes’, (UK
Biobank, 2011), www.ukbiobank.ac.uk/.
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UK Biobank discussed and agreed with its Ethics and Governance Council to amend the scope
of its commitment: rather than destroying participant data, the biobank would commit to ensure
these data would be made completely unusable. UK Biobank subsequently revised both the
participant information materials and governance frameworks not only to reflect this change, but
to also describe the underlying reasons. In effect, such transparency and reflexiveness could
increase participant trust, and ultimately, participation in biobanks.
19.5 challenges and future directions
19.5.1 Resources, Effectiveness and Efficiency of Data Access Governance
Not all research teams or repositories have the guidance, resources or expertise to establish
responsible data access governance. Adequate support from funding agencies and institutions is
key. This support may include establishing community data repositories to store and manage
access on behalf of researchers.
Concerns regarding the workload of DACs in manually reviewing data access requests are the
basis for emerging innovations around automation of at least some parts of the data access
review.27 One example of such efforts has been to automate the review of the conformity of the
proposed data use with any use restrictions attached to the dataset – e.g. a consent agreement
restricting use to non-commercial or disease specific research. In this regard, a recent initiative
supported by the Global Alliance for Genomics and Health (GA4GH) developed a matrix for
machine-readable consent forms. While these technical approaches will support the work
substantially, there will likely always be a need for human review of the most sensitive or
disclosive data access requests.
19.5.2 Coordination between Oversight Bodies
Oversight of access to biomedical databases would benefit considerably from further coordin-
ation between the relevant oversight bodies, such as DACs and RECs.28 A single data-
intensive research project may require access to multiple resources governed by multiple
DACs, meaning multiple forms, reviews and delays. Multi-study DACs, such as METADAC,
address the problem of repeated and time-consuming access processes. Requirements for
multiple approvals from both ethics committees and DACs are dealt with in different ways.
In the UK, for example, ethics review under the Human Tissue Act 2004 provides for broad
approval for data sharing at the biobank level if relevant consents and other ethical safe-
guards are in place; permission for specific data access requests then only needs approval
from the relevant DAC. Where national legislation is not in place, local or consortia
arrangements are possible. The ICGC have disentangled ethics review from data access
request review. Indeed, the ICGC’s DACO consistently maintains that its DAC is not an
ethics review committee and that it should not evaluate the consent forms of users or their
27 S. Dyke et al., ‘Registered Access: Authorizing Data Access’, (2018) European Journal of Human Genetics, 26(12),
1721–1731.
28 E. Dove et al., ‘Ethics Review for International Data-intensive Research’, (2016) Science, 351(6280), 1399–1400; M.
Shabani et al., ‘Oversight of Genomic Data Sharing: What Roles for Ethics and Data Access Committees?’, (2017)
Biopreservation and Biobanking, 15(5), 469–474.
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research protocols, relying instead ‘on the local ethics processes of the data users without
imposing another layer of ethics review requirements on them’.29
19.5.3 Harmonisation of Access Policies and Processes
Interoperability of data access governance supports an important goal of data science, which is to
combine similar datasets together to increase statistical power and thereby produce greater
scientific insight. Access arrangements are currently fragmented, differing across countries,
institutions and databases. These fragmented access arrangements have the potential to under-
mine usability of databases and produce data silos as users battle to conform to a variety of –
sometimes contradictory – access requirements and conditions. Undertaking multiple roughly
similar access processes to access different databases is not only burdensome, it also does
not necessarily improve participant/data subject protections. Different aspects of access review
can be streamlined so that they do not have to be repeated every time a researcher seeks access.
Interoperability and predictability can be improved where different data stewards adopt
standard access criteria. Central access portals could accept single requests to multiple data
resources. This may be possible even where there are differences between the access conditions
applying to the datasets. A step further would be to delegate certain aspects of access review.
A common authentication body, for example, could be responsible for establishing the identity
and affiliation of researchers, who could then present a single set of credentials to different
access bodies.30
19.6 conclusion
Data access governance has an ultimate goal of taking into account and maintaining balance
between the rights and interests of various stakeholders involved in data sharing. A central aim of
data access governance, of course, is to promote broad access to data to advance knowledge and
improve human health. In doing so, it is essential to have a comprehensive overview of the rights
and interests of the involved parties that might be in contrast with each other when establishing
rules for data access reviews and approvals.
In view of increasing data sharing among researchers, it is crucial to ensure the DACs and
RECs have sufficient resources to achieve the ultimate goals of access review, namely transpar-
ency, fairness and proportionality. In doing so, adopting a number of already proposed
approaches would be advantageous, including – partly – automating the process of access review
and introducing light-touch forms of review when sharing non-sensitive data.
Technological advancements could lead to heightened risks of re-identification of individuals
when sharing sensitive health related data. Therefore, it is important to ensure the adopted
governance mechanisms include adequate safeguards when sharing data. In addition, in estab-
lishing governance mechanisms, attention should be paid to the social values underpinning data
sharing. Thereby, the focus of data governance should not be limited to only protecting the
individual rights and interests of the involved parties, but also to fostering social values that can
arise from promoting responsible data sharing.
29 Joly et al., ‘Data Sharing in the Post-Genomic World’.
30 Global Alliance for Genomics & Health, ‘GA4GH Data Use and Researcher ID Work Stream’, (GA4GH), https://
ga4gh-duri.github.io/.
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